Risk factors for lipodystrophy in the CISAI cohort
| Autor: | Fabio Parazzini, GianMarco Vigevani, C. Magnani, Elena Ricci, Paolo Bonfanti, Canio Martinelli, Simona Landonio, Andrea Gabbuti, Cecilia Gulisano, Laura Valsecchi, Timillero L, Luigi Pusterla, Fortuna P, Sebastiano Miccolis, Ivano Faggion, Tiziana Quirino, Silvia Carradori |
|---|---|
| Přispěvatelé: | Bonfanti, P, Gulisano, C, Ricci, E, Timillero, L, Valsecchi, L, Carradori, S, Pusterla, L, Fortuna, P, Miccolis, S, Magnani, C, Gabbuti, A, Parazzini, F, Martinelli, C, Faggion, I, Landonio, S, Quirino, T, Vigevani, G |
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Lipodystrophy Cohort Studies Risk Factors Internal medicine Antiretroviral Therapy Highly Active Epidemiology medicine Humans Age Factor Risk factor HIV Protease Inhibitor Pharmacology Acquired Immunodeficiency Syndrome business.industry Risk Factor Stavudine Age Factors General Medicine HIV Protease Inhibitors Adverse reaction medicine.disease Confidence interval Surgery Antiretroviral therapy Protease inhibitor Cohort Ritonavir Drug Therapy Combination Female Cohort Studie business Cohort study medicine.drug Human |
| Zdroj: | Biomedicinepharmacotherapy = Biomedecinepharmacotherapie. 57(9) |
| ISSN: | 0753-3322 |
| Popis: | Purpose. - This study set out to describe the frequency of lipodystrophy, and identify its risk factors, in HIV-positive patients treated with HAART containing at least one protease inhibitor (PI). We analyzed the data collected in the CISAI study. Method. - The CISAI is a multicenter cohort study that has enrolled 1480 patients. We assessed whether patients had lipodystrophy at a medical visit, with follow-up visits by the same physician at least every 2 months, and also on the basis of patients' own reports. Results. - The lipodystrophy syndrome was detected in about 25% of the patients. Multivariate analysis showed the risk of lipodystrophy was correlated with female sex (RR 1.5; 95% confidence interval, CI, 1.2-2.1), with older age, with homosexuality (RR 1.5; 95% CI 1.0-2.4), with overt disease (RR 1.4; 95% CI 1.1-1.8) and with the duration of treatment before entering this study. The RR for ritonavir was higher than for the other PI (RR 1.4; 95% CI 0.9-1.9). Among patients receiving concomitant antiretroviral therapy the risk of lipodystrophy was greater with stavudine (RR 1.7; 95% CI 1.3-2.3). Conclusions. - The study confirmed the high frequency of the lipodystrophy syndrome among patients treated with PI. © 2003 Éditions scientifiques et médicales Elsevier SAS. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect